Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 28, Issue 10, 2009, Pages

  Silfverdal, Sven Arne ^a   Hogh, Birthe ^b   Bergsaker, Marianne Riise ^c   Skerlikova, Helena ^d   Lommel, Patricia ^e   Borys, Dorota ^e   Schuerman, Lode ^e  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d GPP Practice   (Slovakia)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCAL HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; TREATMENT DURATION; VACCINATION;

EID: 70349662514     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181b48ca3     Document Type: Article

References (47)

1. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-195.
2. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362:355-361.
3. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409. (Pubitemid 32128672)
4. Kilpi T, Ahman H, Jokinen J, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children. Clin Infect Dis. 2003;37:1155-1164.
5. Akkoyunlu M, Ruan M, Forsgren A. Distribution of protein D, an immunoglobulin D-binding protein, in Haemophilus strains. Infect Immun. 1991; 59:1231-1238.
6. Janson H, Ruan M, Forsgren A. Limited diversity of the protein D gene (hpd) among encapsulated and nonencapsulated Haemophilus influenzae strains. Infect Immun. 1993;61:4546-4552.
7. Munson RS Jr, Sasaki K. Protein D, a putative immunoglobulin D-binding protein produced by Haemophilus influenzae, is glycerophosphodiester phosphodiesterase. J Bacteriol. 1993;175:4569-4571.
8. Song XM, Forsgren A, Janson H. The gene encoding protein D (hpd) is highly conserved among Haemophilus influenzae type b and nontypeable strains. Infect Immun. 1995;63:696-699.
9. Janson H, Melhus A, Hermansson A, et al. Protein D, the glycerophosphodiester phosphodiesterase from Haemophilus influenzae with affinity for human immunoglobulin D, influences virulence in a rat otitis model. Infect Immun. 1994;62:4848-4854.
10. Janson H, Carlén B, Cervin A, et al. Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures. J Infect Dis. 1999;180:737-746.
11. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and nontypeable Haemophilus influenzae: a randomized double blind efficacy study. Lancet. 2006;367:740-748.
12. Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28:S66-S76.
13. Wysocki J, Tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J. 2009;28:S77-S88.
14. Chevallier B, Vesikari T, Brzostek J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with routine childhood vaccines. Pediatr Infect Dis J. 2009;28:S109-S118.
15. Concepcion N, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzymelinked immunosorbent assay. Clin Diagn Lab Immunol. 2001;8:266-272.
16. Henckaerts I, Goldblatt D, Ashton L, et al. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. 2006;13:356-360.
17. World Health Organization. Pneumococcal conjugate vaccines. Recommendations for production and control of pneumococcal conjugate vaccines. WHO Tech Rep Ser. 2005;927(Annex 2):64-98.
18. Centers for Disease Control and Prevention, Emory University. Streptococcus pneumoniae opsonophagocytosis using differentiated HL-60 cells (promyelocytic leukemia cell line). Laboratory protocol December 20th 1999. Available at: http://www.vaccine.uab.edu. Accessed 10 February, 2009.
19. Romero-Steiner S, Frash C, Concepcion N, et al. Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol. 2003;10:1019-1024.
20. Henckaerts I, Durant N, De Grave D, et al. Validation of a routine pneumococcal opsonophagocytosis assays to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine. 2007;25: 2518-2527.
21. Melville-Smith ME, Balfour A. Estimation of Corynebacterium diphtheriae antitoxin in human sera: a comparison of enzyme-linked immunosorbent assay with the toxin neutralization test. J Med Microbiol. 1988;25:279-283.
22. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzymelinked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand. 1983;11:137-144.
23. Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med. 1995;332:1280-1284.
24. Poolman J. Pneumococcal vaccine development. Expert Rev Vaccines. 2004;3:597-604.
25. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 1998;101:604-611.
26. Huebner RE, Mbelle N, Forrest B, et al. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr Infect Dis J. 2002;21:1004-1007.
27. Ekström N, Ahman H, Verho J, et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun. 2005;73:369-377.
28. Käyhty H, Åhman H, Eriksonn K, et al. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J. 2005;24:108-114.
29. Esposito S, Pugni L, Bosis S, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months postnatally to pre- and full-term infants. Vaccine. 2005;23:1703-1708.
30. Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of CRM-conjugated 7-valent pneumococcal conjugate vaccine (PCV7) administered at 2-dose (4 and 6m) or 3-dose primary regimen (2, 4 and 6m) with a booster at 12m.-Abstract P3-049 . In: 6th International Symposium on Pneumococci and Pneumococcal Diseases; June 8-12, 2008; Reykjavik, Iceland. Abstract 308.
31. Sigurdardottir ST, Davidsdottir K, Arason VA, et al. Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9cPnC-MnCC) whether given in two or three primary doses. Vaccine. 2008;26:4178-4186.
32. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502.
33. Schmitt HJ, Faber J, Lorenz I, et al. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine. 2003;21:3653-3662.
34. Tichmann-Schumann I, Soemantri P, Behre U, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2005;24:70-77.
35. Knuf M, Habermehl P, Cimino C, et al. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine. 2006;24:4727-4736.
36. Tejedor JC, Moro M, Ruiz-Contreras J, et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria- tetanusacellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal Ctetanus toxoid conjugate vaccine. Pediatr Infect Dis J. 2006;25:713-720.
37. Peeters C, Tenenbergen-Meekes AM, Poolman JT, et al. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun. 1991;59:3504-3510.
38. Granoff D, Holmes S, Belshe R, et al. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA. 1994;272:1116-1121.
39. Kurikka S, Käyhty H, Saarinen L, et al. Immunologic priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy. J Infect Dis. 1995;172:1268-1272.
40. Schuerman L, Prymula R, Henckaerts I, et al. ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media. Vaccine. 2007;25:1962-1968.
41. Prevenar summary of product characteristics 6th January 2009. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/prevenar/prevenar.htm.
42. O'Brien KL, Levine OS. Effectiveness of pneumococcal conjugate vaccine. Lancet. 2006;368:1469-1470.
43. Kaye P, Andrews N, Slack M, et al. Vaccine effectiveness and indirect protection from pneumococcal conjugate vaccine used in a 2 dose infant priming plus booster schedule in England and Wales Abstract P3-118 . In: 6th International Symposium on Pneumococci and Pneumococcal Diseases; June 8-12, 2008; Reykjavik, Iceland. Abstract 355.
44. Vestrheim DF, Løvoll O, Aaberge IS, et al. Effectiveness of a 2 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine. 2008;26:3277-3281.
45. De Wals P, Bolduc D, Boulianne N, et al. Impact of a Three-Dose Pneumococcal Conjugate Vaccine Program on the Epidemiology of Pneumococcal- Related Outcomes in the Province of Quebec, Canada. Abstract G-1003 . In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract 277.
46. Andersen PH. Epi-Nyt no 38, 17 Sept 2008. Available at: www.ssi.dk. epinyt@ssi.dkandhttp://www.ssi.dk/graphics/dk/nyheder/epinyt/2008/PDF/ epinyt-38--2008.pdf.
47. Dagan R, Givon-Lavi N, Janco J, et al. Nasopharyngeal carriage of S. pneumoniae vaccine serotypes (VT-Sp) in first 2 years of life following 4 different 7-valent CRM-conjugate vaccine (PCV7) schedules.-Abstract P3-046 . In: 6th International Symposium on Pneumococci and Pneumococcal Diseases; June 8-12, 2008; Reykjavik, Iceland. Abstract 306.